|
|
|
|
| |
R&D Capacity |
 |
Strong team consisting of over 200 specialists |
 |
R & D expenditure occupies 6%-8% of annual sales |
 |
Capable of conducting cross board pre-clinical studies independently for areas like pharmacology, drug analysis, safety evaluation and clinical trials |
 |
Focused on new drug discovery, drug delivery system development, DDS platform including Long-acting Extended-Release Microspheres for Injection and Liposome Technology Platform |
 |
221 China Patents filed, of which 40 were granted |
 |
10 PCT (6 granted) |
| |
R&D Platform |
 |
|
 |
Key technology - Sustained-release formulation of biodegradable microspheres and pellet
|
Long-acting Extended-Release Microspheres for Injection |
|
Microsphere preparation for injection is a novel drug formulation, in which drug molecules are dissolved or dispersed in the polymers carrier to form particle disperse system with the diameter at 0.01~200 ¦Ì m. After injection into human body, according to the administration requirements, the active ingredients of microspheres can be controlled to release within several days or several years at a uniform speed. | |
 |
Key technology - Liposome DDS Technology
|
Liposome Technology |
|
Liposome is one kind of targeting drug vectors £¬ which is a newly innovated targeting drug DDS formulation. It is made up of small vesicles with phospholipid bilayers similar to bio-membrane structure. This technology allows embedding drugs into liposome particles with the diameter of submicron and nanometer. These particles have the structure similar to biological cell membrane and can be biodegraded in the body without immunogenicity. | |
 |
Therapeutic potency evaluation both in Vivo and in Vitro |
 |
Safety evaluation |
 |
ADME evaluation both in animal and human body |
| |
R&D Global Collaboration Objectives |
 |
In-license drugs are currently at development stage. We focus on specialty drugs in Oncology, Cardiovascular, CNS system,Hepatology, Gastroenterology, Orthopaedics. |
 |
Out-license our own proprietary pipeline drugs (New formulation and NCE derived from natural herbs). |
 |
Co-develop pre-clinical stage (pharmacology and toxicology) and clinical stage (phase I, II, and III) drug candidates. |